Part 7/8:
Califf also addressed the challenge of maintaining confidentiality and the integrity of the FDA's processes. With the increasing influence of major corporations and individuals like Musk in government affairs, there are substantial risks to public health policies that could be compromised by corporate interests. The FDA's commitment to safeguarding sensitive information from human clinical trials and drug development must remain intact to ensure public trust and safety.